Northwest Biotherapeutics (NWBO) Cash from Operations (2010 - 2026)
Northwest Biotherapeutics (NWBO) posted quarterly Cash from Operations of 12509000.0 for Q1 2026, down 32.82% year-over-year from 18620161.53 in Q1 2025, and up 15.27% quarter-over-quarter from 14764000.0 in Q4 2025.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Cash from Operations (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 12509000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 32.82% year-over-year to 12509000.0; the TTM figure through Mar 2026 stood at 47854000.0 (up 11.43% YoY), while the FY2025 annual figure was 44763000.0, up 21.49% from the prior year.
- Cash from Operations for Q1 2026 stood at 12509000.0, up from 14764000.0 in the prior quarter.
- The five-year high for Cash from Operations was 6688000.0 in Q2 2025, with the low at 20181000.0 in Q4 2024.
- The 5-year median for Cash from Operations is 12967000.0 (2022), against an average of 12982411.76.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations sank 129.83% in 2022, then soared 58.71% in 2025.
- Northwest Biotherapeutics' Cash from Operations stood at 8849000.0 in 2022, then plunged by 91.64% to 16958000.0 in 2023, then fell by 19.01% to 20181000.0 in 2024, then grew by 26.84% to 14764000.0 in 2025, then gained by 15.27% to 12509000.0 in 2026.
- Business Quant data shows NWBO's Cash from Operations at 12509000.0 in Q1 2026, 14764000.0 in Q4 2025, and 13893000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | -7.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.17 Mn |
| Mar 31, 2026 | -12.51 Mn |
| Dec 31, 2025 | -14.76 Mn |
| Sep 30, 2025 | -13.89 Mn |
| Jun 30, 2025 | -6.69 Mn |
| Mar 31, 2025 | -9.42 Mn |
| Dec 31, 2024 | -20.18 Mn |
| Sep 30, 2024 | -8.23 Mn |
| Jun 30, 2024 | -16.20 Mn |
| Mar 31, 2024 | -12.41 Mn |
| Dec 31, 2023 | -16.96 Mn |
| Sep 30, 2023 | -13.92 Mn |
| Jun 30, 2023 | -11.52 Mn |
| Mar 31, 2023 | -11.24 Mn |
| Dec 31, 2022 | -8.85 Mn |
| Sep 30, 2022 | -16.12 Mn |
| Jun 30, 2022 | -14.84 Mn |
| Mar 31, 2022 | -12.97 Mn |
| Dec 31, 2021 | -11.25 Mn |
| Sep 30, 2021 | -7.01 Mn |